Harrow
Harrow Inc is an American ophthalmic biopharmaceutical enterprise producing specialized eye care medicines and compounded formulations. The company commercializes FDA-approved branded ophthalmic therapies, including Iveezy, Vevye, and Vigamox, alongside operating ImprimisRx, a leading ophthalmic compounding pharmacy. Main revenue drivers consist of commercial drug sales of proprietary branded ophthalmic pharmaceuticals and compounded eye drop formulations billed to eye care clinics. Harrow serves ophthalmologists, optometrists, ambulatory surgery centers, and eye care patients across the United States. The company holds a market-leading position in North America for specialized ophthalmic compounding and niche eye care therapeutics. Headquartered in Nashville, Tennessee, Harrow Inc is listed on the Nasdaq Stock Market.
3 of the funds FundTelligence covers report a position in Harrow.
- Legal name
- HARROW
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Harrow
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- FTGF Putnam US Research Fund — Franklin Templeton · 0.05 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)